anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain a bleaching agent excellent in prophylactic and improving effects on pigmentation of skin and capable of carrying out the prophylaxis and treatment of dermal stains and ephelides due to sunburn, etc., by including a specific phytosphingosine derivative or its salt as an active ingredient. SOLUTION: This bleaching agent is obtained by including a phytosphingosine derivative represented by the formula (R1 is a 6-26C hydrocarbon, R2 and R3 are each H or a 1-4C hydrocarbon) or its salt as an active ingredient in an amount of preferably 0.001-30 wt.% based on the total composition. The compound represented by the formula is obtained by, e.g. extracting a phospholipid, a sphingoglycolipid, etc., containing the compound from a suitable tissue (e.g. a bovine brain) or a cultured product (e.g. a yeast) and hydrolyzing the resultant extract. The phytosphingosine derivative has effects on the disappearance of the UV-B pigment unevenness (melanin suppressing effects) and bleaching effects are thereby exhibited by formulation thereof in medicines or cosmetics, etc.  The existing bleaching agent (e.g. arbutin or kojic acid) is used together therewith to thereby exhibit better bleaching effects.
A controlled release dosage unit contains a plurality of cores each consisting of a therapeutically active material admixed with an ingestible material resistant to disintegration in the gastrointestinal tract, of which a minor proportion are coated. The coated cores have alternating coatings of therapeutically active material and ingestible material.  The amount of the former in the cores and in the coatings being so correlated that the percentage in the cores and coatings released during the first hour in the gastro-intestinal tract after accidental crushing of the dosage unit in the mouth is less than 50% of the total therapeutically active content of the dosage unit.  The therapeutically active material may be an antibiotic, sedative, hypnotic, hypotensive, vasodilator, hormone, vitamin, tranquillizer (examples being given) or an amphetamine, pentylene tetrazole, N-acetyl-p-aminophenol, Belladonna alkaloids, atropine sulphate, Hyoscine hydrobromide, Hyoscyamine sulphate, chlorpheniramine maleate, phenylephrine, quinidine salts, theophylline salts, ephedrine salts, pyri/amine maleate, or guiacolglyceryl-ether-theophyllinate.  The ingestible materials may be methyl or ethyl cellulose, cellulose acetate or phthalate, shellac, castor oil, hydrogenated castor oil, waxes e.g. beeswax, carnauba, candelilla, Japan, paraffin or bayberry; higher fatty acids e.g. oleic, palmitic, or stearic, esters thereof e.g. glyceryl tristearate, cetyl palmitate, diglycol stearatate, glyceryl myristrate, or triethylene glycol monostearate; fatty alcohols e.g. cetyl or stearyl alcohol, polyethylene glycols e.g. "Carbowax" (Registered Trade Mark), polyethylene glycol stearates, polyoxyethylene stearate, glyceryl mono-stearates, or mixtures thereof.
Bioengineered collagen constructs with antimicrobial properties are provided.  The bioengineered collagen constructs comprise a sheet-like layer of purified collagenous tissue matrix derived from a tissue source, such as the tunica submucosa of small intestine or a processed intestinal collagen layer derived from the tunica submucosa of small intestine, treated with an antimicrobial agent. The constructs arc biocompatible. The present invention has a variety of applications, including wound dressing and surgical repair devices. Methods for treating a damaged or diseased soft tissue are provided. Methods for treating a wound in need of care and treatment are also disclosed.
Frames of a video frame sequence capturing one or more skin regions of a body are provided to a first neural network. The first neural network generates respective appearance representations based on the frames. An appearance representation generated based on a particular frame is indicative of a spatial distribution of a physiological signal across the particular frame. Simultaneously with providing the frames to the first neural network, the frames are also provided to a second neural network. The second neural network determines the physiological signal based on the frames. Determining the physiological signal by the second neural network includes applying the appearance representations, generated by the first neural network, to outputs of one or more layers of the second neural network to emphasize regions, in the frames, that exhibit relatively stronger presence of the physiological signal and deemphasize regions, in the frames, that exhibit relatively weaker presence of physiological signal.
Obese adult male smoker subjects in this cohort will take part in 4 treatment periods with one of the following treatments in each period. Subjects will receive single dose of all four treatments (one per period) in a random order. Treatment A = 15 mg GSK2256294 capsules, Treatment B = 40 mg GSK2256294 capsules, Treatment C = 100 mg GSK2256294 capsules, Treatment P = Matched Placebo capsules.
The patients diagnosed with black triangles according to Norland classification system for loss of papillary height will be selected. Each patient will receive a proper knowledge of the study protocols along with full-mouth scaling and root planing (SRP) using ultrasonic and hand instruments and will be given personalized oral hygiene instructions. After oral prophylaxis and baseline measurements of insufficient interdental papilla the treatment will be MN and iPRF. First, MN will be done in the required area with insulin syringe gauge 30,The interdental papilla will vertically and horizontally measured in mm. By establishing a ratio and proportion, the number of microchannels in the region to be treated will calculated to be 250 microchannels per square cm. Then, a venous blood sample will be taken for each patient using a 10-ml injector into i-PRF tube containing no anticoagulant and centrifuged at room temperature for 3 min at 700 rpm (60 g force). The 30-gauge dental injector needles will be used for injection of i-PRF. The needle will be inserted at 45° angle, 2-3-mm apical to the involved papilla and all surrounding areas will receive iPRF. Each involved papilla will be injected with an amount till blanching is visible . This method will be repeated for 4 times at 10 days intervals consecutively. The final clinical photographs and measurements will recorded 3 and 6 months of last dose administered . After the intervention, patients will receive oral hygiene instructions that include the roll technique when brushing without the use of floss and toothpick during the study period to minimize trauma to the treated site .
BACKGROUND: The aim of this study was to evaluate effectiveness and safety of laparoscopic lateral suspension in women affected by high grade uterine prolapse associated to anterior defect. The secondary endpoint is to evaluate mid-term impact on Quality of Life and sexual function.
METHODS: A multicenter retrospective study on women undergoing laparoscopic lateral suspension for uterine prolapse ≥III stage was performed. We included 174 women, but due to exclusion criteria, 134 patients were enrolled for this study. Preoperative evaluation consisted of an urogynecological interview, clinical exam, 3-day voiding diary and urodynamic testing; the prolapse Quality of Life Questionnaire was used to quantify the impact of prolapse symptoms on Quality of Life and the Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire short form, the Female Sexual Function Index and the Female Sexual Distress Scale were administered to evaluate sexual function before surgical intervention and at median follow-up of 3.8 years.
RESULTS: We included 134 women with uterine prolapse ≥III stage. All patients underwent laparoscopic lateral suspension, 8 also posterior colporrhaphy and 5 also transobturator tape insertion. POP-Q classification score for anterior and apical compartment showed a significant average decrease. The surveys administered to patients showed an improvement in Quality of Life, an increase in the number of monthly intercourses and a significant improvement in sexual life after surgery.
CONCLUSIONS: Laparoscopic lateral suspension for pelvic organ prolapse correction is a safe and effective technique for uterine and anterior associated defect. Quality of Life and sexual function significantly improved after surgery.
Although in clinical practice, thawed embryos with appropriate development time will be selected strictly according to the number of days after ovulation, there are still two problems in actual clinical treatment: one is the embryonic factor, although the rate of embryonic development is generally the same, However, the phenomenon of delayed embryo division and development often occurs. The second is the endometrial factor. There are reports that a small number of people will move the transplant window forward, or the transplant window is narrow. This potentially creates the risk of embryo-endometrial mismatch. Based on this, the research team focused on patients with frozen embryo transfer cycles and put forward the strategy of "thawing embryos in advance and prolonging the development period of embryos properly" in an effort to achieve better repair of damage caused by embryo freezing and fine-tuning of embryo-endometrial interaction time. Therefore, it is necessary to compare thawing embryos in advance and thawing on the day of transfer on pregnancy outcomes in patients with repeated transplant failure and routine patients respectively.

The purpose of this study is to analyze which way can improve clinical pregnancy and birth outcomes, is there a significant difference between the two ways or two types of patients?
The invention discloses a traditional Chinese medicine composition for treating persistent hepatitis and a preparation method thereof. The traditional Chinese medicine is prepared by using Chinese medicinal herbs such as root of red-rooted salvia, paenoiae alba, mrlberrt fruit, fruit of Chinese wolfberry, fructus ligustri lucidi and bell cricket. The red-rooted salvia can invigorate and promote the blood circulation and adjust the sanguimotor and has the function of dredging for reinforcement; scientific experiments prove that the traditional Chinese medicine has the function of vitamin E and can play a role of freeing the liver. The paenoiae alba is matched to enable the liver not to be fired for nourishment. The paenoiae alba and the red-rooted salvia are combined for nourishing the blood without coagulating blood and smoothing the stasis without damaging the health; the mrlberrt fruit, the fruit of Chinese wolfberry and the fructus ligustri lucidi are added for nourishing the liver and smoothing the blood, improving eyesight and dredging the tendons; and the bell cricket is introduced for releasing liver qi and smoothing the channels and has the efficacy of nourishing blood and liver and smoothing qi. The composition has the characteristics of no toxic and side effect, convenient taking, high healing rate and remarkable effect, and is worthy of being popularized and used in clinic.
The present invention relates to a Chinese medicinal compound preparation for treating female dysmenorrhoea and a preparation method thereof. The compound preparation comprises components of the following proportion by weight: 180 to 220 of white peony root, 25 to 35 of nutgrass galingale rhizome, 20 to 30 of Chinese angelica, 15 to 25 of notoginseng, 2 to 6 of carbonized argy wormwood leaf, 40 to 60 of lilyturf root, 20 to 40 of tangshen and 120 to 180 of motherwort. The extract of the medicines of the proportion is matched with proper kinds of auxiliary materials or matrices in the pharmacy and made into soft capsules and dispersive tablets. The clinical observation indicates that the Fukangning soft capsules and the Fukangning dispersive tablets have particularly good curative effects on patients with short-term dual depletion of qi and blood and abdominal pain during menstruation. Compared with Fukangning tablets, the compound preparation can obviously shorten medication time. After being tested, the therapeutic effects are superior to those of the Fukangning tablets; the compound preparation has high cure rate. Evaluated from the medicinal preparation, the Fukangning soft capsules and the Fukangning dispersive tablets dissolve effective components more sufficiently and rapidly and are obviously better than the compared tablets.
The first dose of the IMP is administered in the evening prior to the surgical procedure. Administrations of the study drug follow a 1-0-1 schedule (colchicine 0.5 mg per intake). The last study drug is administered in the evening of the third postoperative day.
A kit and method for providing a “second line of defense” against Corona Virus strains. The kit includes at least one nasal swab pre-moistened with an iodine solution, and at least one oral swab pre-moistened with a chlorhexidine solution. The iodine solution can be a solution of betadine 0.5-2.0%, or a povidone solution. The chlorhexidine solution is chlorhexidine 0.09% to 0.12%. The nasal swabs are preferably sealed in a resealable package. The oral swabs are preferably sealed in a separate resealable package. The kit can include alcohol swabs pre-moistened with 60%-70% Isopropyl Alcohol in a disposable sealed package. The method includes using at least one nasal swab pre-moistened with an iodine solution to apply the iodine solution to an inner surface within each of one's nostrils, and using at least one oral swab pre-moistened with chlorhexidine solution to apply the chlorhexidine solution to an inner surface of one's mouth.
Efprezimod alfa: IV infusion, 480 mg (day -1), 240 mg (day +14) and 240 mg (day +28); Tacrolimus: begin on day -3. IV \[0.03 mg/kg/day\] or by mouth (PO) \[0.045 mg/kg/dose\] dosing is permitted; Methotrexate: given IV at a dose of 15 mg/m\^2/dose once daily on Day 1 after hematopoietic cell transplantation (HCT), and at a dose of 10 mg/m\^2/dose on days 3, 6, and 11 after HCT.
The pattern and incidence of adverse events and laboratory abnormalities recorded during pediatric clinical trials are comparable to those seen in adults.   
  
In Phase II/III clinical trials conducted in the United States and in Europe, 577 pediatric patients, ages 1 day to 17 years were treated with fluconazole at doses up to 15 mg/kg/day for up to 1,616 days. Thirteen percent of children experienced treatment-related adverse events. The most commonly reported events were vomiting (5%), abdominal pain (3%), nausea (2%), and diarrhea (2%). Treatment was discontinued in 2.3% of patients due to adverse clinical events and in 1.4% of patients due to laboratory test abnormalities. The majority of treatment-related laboratory abnormalities were elevations of transaminases or alkaline phosphatase. 

To report SUSPECTED ADVERSE REACTIONS contact AvKARE, Inc. at 1-855-361-3993; email drugsafety@avkare.com; or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
PURPOSE:To provide the cerebral metabolism-stimulating and cerebral function- improving agent containing the extract of Asparagus.linearis of Leguminosae plant as an active ingredient, and capable of activating cerebral metabolism and of rapidly treating and improving cerebral memory and cerebral functions. CONSTITUTION:The cerebral metabolism-stimulating and cerebral function- improving agent contains as an active ingredient the extract obtained by extracting the leaves or stems of Asparagus.linearis belonging to the genus Leguminosae with water and/or an organic solvent (e.g. methanol). The extract is suitably mixed with conventional medicinal carrier, excipient, binder, diluent, etc., and subsequently prepared into preparations. The preparations can include granules, powder, capsules, coatings, syrups, suppositories, injections, etc. The agent is preferably drunk at a dose of 100-1500ml/day as a solution of 1-5g dried leaves/liter, when commonly administered as a drink. The agent can treat and improve cerebral diseases and neuropathy such as senile dementia and Parkinsonism.
Genetic polymorphisms that impair very low-density lipoprotein (VLDL) secretion are linked to hepatic steatosis, fibrosis, and hepatocellular cancer. Liver-specific deletion of microsomal triglyceride transfer protein (Mttp-LKO) impairs VLDL assembly, promoting hepatic steatosis and fibrosis, which are attenuated in Mttp-LKO X Fabp1-null [Fabp1/Mttp double knockout (DKO)] mice. The current study examined the impact of impaired VLDL secretion in Mttp-LKO mice on hepatocellular cancer incidence and progression in comparison to Fabp1/Mttp DKO mice. Diethylnitrosamine-treated Mttp-LKO mice exhibited steatosis with increased tumor burden compared with flox controls, whereas diethylnitrosamine-treated Fabp1/Mttp DKO mice exhibited a paradoxical increase in tumor burden and >50% mortality by 50 weeks. Serum high-density lipoprotein cholesterol was elevated in both Mttp-LKO and Fabp1/Mttp DKO mice, with increased intratumoral expression of apolipoprotein A1 and apolipoprotein E. Lipidomic surveys revealed progressive enrichment in distinct triglyceride species in livers from Mttp-LKO mice with further enrichment in Fabp1/Mttp DKO mice. RNA sequencing revealed mRNA changes suggesting altered monocarboxylic acid use and increased aerobic glycolysis, whereas hepatocytes from Fabp1/Mttp DKO mice exhibited increased capacity to use glucose and glutamine. These metabolic shifts were accompanied by reduced expression of HNF1 homeobox A (HNF1a), which correlated with tumor burden. Taken together, these findings demonstrate that hepatic tumorigenesis is increased in mice with impaired VLDL secretion and further accelerated via pathways including altered fatty acid compartmentalization and shifts in hepatic energy use.
Esophageal cancer (EC) continues to be a major health burden worldwide. The 5-year survival rates for esophageal cancer have remained less than 15% over decades, probably because of ineffective therapies and the detection of late-stage cancers. Concurrent chemo-radiotherapy was established as one of the viable options for therapy of patients with localized EC following the results from the landmark trial of the Radiation Therapy Oncology Group (RTOG) 85-01 trial, showing a significant survival advantage of concurrent chemoradiation over radiation alone.

The use of radiochemotherapy with cisplatin and 5-fluorouracil (5-FU) is a well-accepted standard for the definitive treatment of esophageal cancer in China which has also been demonstrated efficacy and good tolerability internationally. The AJCC recommended dose range of radiotherapy for concurrent therapy is 45-50.4Gy. Moreover, (RTOG) 85-01 trial also established 50.4 Gy as the standard dose of radiation to be administered concurrently with chemotherapy. However, the appropriate dose of radiation fit for Chinese remains controversial. Due to insufficient evidence of EBM, radiation therapist in China always prescribe a radiation dosage by their own experience. Dosages (e.g. 60-64Gy) significantly higher than the international standard is commonly used in Chinese EC patients which lead to a greater likelihood of toxicity. Thus Chinese oncologists are urgent to reach a consensus about radiation dosage in the standard treatment of local advanced EC.
The growing number of prevalent arteriovenous (AV) accesses has been associated with an increase in the incidence of procedures being performed to maintain patency. To reduce the rate of unnecessary procedures, the 2019 Kidney Disease Outcome Quality Initiative guidelines addended the AV access surveillance recommendations, which includes clinical monitoring and assessment of dialysis adequacy alone. Abnormal clinical findings would necessitate follow-up angiography with or without confirmatory duplex ultrasound. Due to poor patency, increased surveillance schedules have been proposed to identify stenosis early and potentially prevent acute thrombotic events and AV access failure. In this review, we outlined current AV access monitoring and maintenance procedure recommendations, as described by the Centers for Medicare and Medicaid Services and 2019 Kidney Disease Outcome Quality Initiative guidelines. In addition, we highlight the findings of recently published randomized controlled trials that have examined increased surveillance schedules.
Study I was a 12-month, randomized, double-blind, parallel-dose-group, multinational trial in 25 patients age 4 years and older with Gaucher disease-related anemia and either thrombocytopenia or organomegaly. Patients were not allowed to have had disease-specific therapy for at least the previous 30 months; all but one had no prior therapy. The mean age was 26 years and 60% were male. Patients were randomized to receive VPRIV at a dose of either 45 Units/kg (N=13) or 60 Units/kg (N=12) every other week. The recommended starting dose in naïve patients is 60 Units/kg. The 45 Units/kg dosage is not recommended as a starting dose in naïve patients [see Dosage and Administration (2.1)].

At baseline, mean hemoglobin concentration was 10.6 g/dL, mean platelet count was 97 × 109/L, mean liver volume was 3.6 % of body weight (% BW), and mean spleen volume was 2.9 % BW.

For all studies, liver and spleen volumes were measured by MRI. The changes in clinical parameters after 12 months of treatment are shown in Table 2. The observed change from baseline in the primary endpoint, hemoglobin concentration, was considered to be clinically meaningful in the 60 Units/kg dose, in light of the natural history of untreated Gaucher disease.

Study II was a 9-month, randomized, double-blind, active-controlled (imiglucerase), parallel-group, multinational study in 34 patients age 4 years and older. Patients were required to have Gaucher disease-related anemia and either thrombocytopenia or organomegaly. Patients were not allowed to have had disease-specific therapy for at least the previous 12 months. The mean age was 30 years and 53% were female; the youngest patient who received VPRIV was age 4 years. Patients were randomized to receive either 60 Units/kg of VPRIV (N=17) or 60 Units/kg of imiglucerase (N=17) every other week.

At baseline, the mean hemoglobin concentration was 11.0 g/dL, mean platelet count was 171 × 109/L, and mean liver volume was 4.3 % BW. For the patients who had not had splenectomy (7 in each group) the mean spleen volume was 3.4 % BW. After 9 months of treatment, the mean absolute increase from baseline in hemoglobin concentration was 1.6 g/dL ± 0.2 (SE) for patients treated with VPRIV. The mean treatment difference in change from baseline to 9 months [VPRIV – imiglucerase] was 0.1 g/dL ± 0.4 (SE).

In both studies, examination of age and gender subgroups did not identify differences in response to VPRIV among these subgroups. The number of non-Caucasian patients in these studies was too small to adequately assess any difference in effects by race.

In Study IV, treatment naïve patients were administered VPRIV. Treatment-naïve patients continued to show improvements in clinical parameters (hemoglobin concentration, platelet count, liver volume, and spleen volume) compared with baseline for up to 60 months of treatment with ERT.
The object of this study is to find the early mortality prognostic biomarkers within the hemostatic system in sepsis patients. Blood samples will be collected from sepsis patients at admission. Parameters reflect endothelial injury, such as thrombomodulin (TM), tissue type plasminogen activator inhibitor complex (tPAIC), parameters reflect procoagulation condition, such as thrombin-antithrombin complex (TAT), and parameters reflect hyperfibrinolysis, such as plasmin-plasmin inhibitor complex (PIC) will be tested. Based on the results of these parameters, sepsis patients will be divided into coagulation parameter normal or abnormal groups. Twenty-eight days of mortality will be determined by patient follow-up. Regression analysis will be used to evaluate the relationship between these parameters and the mortality of sepsis patients.